Rxsight Inc
NASDAQ:RXST
Rxsight Inc
Net Issuance of Common Stock
Rxsight Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Rxsight Inc
NASDAQ:RXST
|
Net Issuance of Common Stock
$106m
|
CAGR 3-Years
363%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Haemonetics Corp
NYSE:HAE
|
Net Issuance of Common Stock
-$67.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
19%
|
CAGR 10-Years
-14%
|
||
ICU Medical Inc
NASDAQ:ICUI
|
Net Issuance of Common Stock
$5.9m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-13%
|
||
Align Technology Inc
NASDAQ:ALGN
|
Net Issuance of Common Stock
-$423.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-23%
|
||
Lantheus Holdings Inc
NASDAQ:LNTH
|
Net Issuance of Common Stock
$7.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
||
Merit Medical Systems Inc
NASDAQ:MMSI
|
Net Issuance of Common Stock
$19.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
Rxsight Inc
Glance View
In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life. Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.
See Also
What is Rxsight Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
106m
USD
Based on the financial report for Dec 31, 2023, Rxsight Inc's Net Issuance of Common Stock amounts to 106m USD.
What is Rxsight Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
363%
Over the last year, the Net Issuance of Common Stock growth was 1 253%. The average annual Net Issuance of Common Stock growth rates for Rxsight Inc have been 363% over the past three years .